ENA Respiratory announced that it has received a contract extension from the US Department of Defense (DoD), providing additional funds for continued development of INNA-051, a dry powder intranasal TLR2/6 agonist. In January 2023, ENA Respiratory announced that the DoD had provided funding to develop a dry powder formulation of the antiviral, which had previously been a liquid formulation.
According to the company, the new funding of more than $3 million will support expansion of a recently-initiated Phase 1b study of INNA-051 to add younger subjects. ENA says that the Phase 1b trial, which was originally designed to evaluate the nasal powder in subjects over age 60, will now be modified to include subjects aged 18 to 45.
ENA Respiratory CEO Christophe Demaison commented, “This new funding from the DOD is further recognition of the potential of INNA-051 to play a significant role in protecting individuals at risk of serious harm from respiratory viral infections, including those with occupational risk. We are grateful to the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense for its continued support.”
Read the ENA Respiratory press release.
